Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Anti-CD22 CAR T cells|
Anti-CD22 CAR T cells are T-cells that have been engineered to express a chimeric antigen receptor (CAR) that targets CD22, potentially resulting in enhanced anti-tumor immune response against CD22-expressing tumor cells (NCI Drug Dictionary).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Anti-CD22 CAR T cells||CD22 CAR-T|anti-CD22 CAR-expressing T lymphocytes||CD22 Immune Cell Therapy 12||Anti-CD22 CAR T cells are T-cells that have been engineered to express a chimeric antigen receptor (CAR) that targets CD22, potentially resulting in enhanced anti-tumor immune response against CD22-expressing tumor cells (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04088890||Phase I||Anti-CD22 CAR T cells Cyclophosphamide + Fludarabine||Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies||Recruiting||USA||0|
|NCT02315612||Phase I||Anti-CD22 CAR T cells||Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies||Suspended||USA||0|
|NCT04815356||Phase I||Anti-CD22 CAR T cells||Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant||Recruiting||USA||0|
|NCT04088864||Phase I||Anti-CD22 CAR T cells Cyclophosphamide + Fludarabine||CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies||Suspended||USA||0|
|NCT02650414||Phase I||Anti-CD22 CAR T cells||CD22 Redirected Autologous T Cells for ALL||Recruiting||USA||0|